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Abstract 
BACKGROUND: Interleukin-18 (IL-18) and Tumor Necrosis Factor-alpha (TNF-α) are proinflammatory cytokines 
that increased the development of Th1 immune response, but have a different type of regulation of the gene 
expression. Whereas TNF-α has an inducible expression, IL-18 is translated as an inactive protein and required 
proteolytic cleavage by Casp-1 in inflammasome complexes. 
AIM: To investigate the effect of the histone deacetylases inhibitor Suberoylanilide Hydroxamic Acid (SAHA) on 
the gene expression and secretion of both cytokines, IL-18 and TNF-α, according to their contribution to the 
cancer development and anticancer immunity. 
METHODS: Isolated peripheral blood mononuclear cells (PBMC) were stimulated with LPS and C3bgp with or 
without SAHA. Cytokine production was assessed by ELISA at 6 and 24h. 
RESULTS: IL-18 and TNF-α secretion was significantly increased at 6h and 24h in response to stimulation. TNF-
α production from stimulated PBMC was downregulated by SAHA at 6 and 24h. Treatment with SAHA does not 
inhibit the secretion of IL-18 significantly either at 6 or 24h of stimulation. 
CONCLUSION: The inhibition of histone deacetylases by SAHA does not influence the inflammasome-dependent 
production of immunologically active IL-18. In contrast, the production of proinflammatory TNF-α in cultures was 
mediated by the activity of HDAC class I and class II enzymes. 
 
 
 
 
 
Introduction 
 
The inducible cytokine release is regulated at 
several levels started from chromatin remodelling 
allowing gene expression and finalised with protein 
secretion. Before transcription, the gene region must 
be accessible to the transcriptional factors binding. 
The key role in this process has the histone 
modification mainly acetylation and deacetylation. 
Two classes of enzymes drive the acetylation status 
of the chromatin. Acetyltransferases open the 
chromatin conformation by histone acetylation and 
allow the transcriptional process. Histone 
deacetylases (HDACs) compress the chromatin 
structure triggering the gene silence by deacetylation 
[1][2]. HDACs are divided into four classes. Of them, 
class I are resident to the nucleus, where they act as 
histone modifiers and repressors of the transcription. 
Histone deacetylases class II is moving between the 
nucleus and cytoplasm. They can regulate the gene 
expression also by the changes in 
acetylation/deacetylation status of other proteins 
[3][4].  
Recently, a new class of small organic 
molecules-HDAC inhibitors (HDI), which abolish the 
action of HDACs, are intensively studied, especially 
about cancer and inflammatory diseases treatment 
[5][6]. They regulate the expression up to 10% of the 
cellular genes by affecting enzymes including in 
chromatin remodelling complex and recruiting of the 
transcription factors [7]. Although the histone 
acetylation is linked to an increased transcription; HDI 
also can increase the expression of some genes by 
the still unclear mechanism. Suberoylanilide 
Hydroxamic Acid (SAHA) is the HDI interacting with 
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class I and class II histone deacetylases [4]. SAHA 
was the first HDI approved by U. S. Food and Drug 
Administration for the treatment of some malignant 
disease as CTCL [8].  
During the early phase of the immune 
response, binding of microbial antigens (especially 
those referring to pathogen-associated molecular 
patterns-PAMPs) to pattern recognition receptors 
(PRR) of the immune cells, activate intracellular 
signalling pathways, which in turn lead to alteration in 
cell behaviour and gene expression. As a 
consequence soluble mediators are synthesised and 
secreted by the activated immune cells including 
proinflammatory and immunoregulatory cytokines like 
TNF-α and IL-18. Tumor necrosis factor-alpha (TNF-
α) was first discovered as mediating cell death of 
some malignant cells. Recently, a growing body of 
evidence showed that TNF-α has a tumour-promoting 
role as a key mediator of chronic inflammation which 
drives the cancer development [9]. TNF-α is secreted 
as a soluble 17-kDa molecule after processing of 
membrane-bound TNF-α by constitutive expressed 
membrane TNF-α converting enzyme [10], mainly by 
the activated macrophages/monocytes. Interleukin-18 
(IL-18) is also a proinflammatory cytokine, but it is 
included in Th1 polarisation. It’s inducible gene 
expression after recognition of PAMPs by PRR lead to 
the synthesis of an inactive protein (pro – IL-18). Pro – 
IL-18 is converted into biologically active IL-18 by 
another activation pathway in inflammasome 
complexes through caspase 1-mediated cleavage 
[11]. IL-18 is involved in the development of 
successful antitumor immunity through its ability to 
induce IFN-γ secretion [12]. Unlike TNF-α, the 
mechanisms regulating IL-18 processing and 
secretion remains not well understood.  
In this regard, our study was designed to 
investigate the SAHA effect on protein synthesis and 
release of TNF-α and IL-18 from stimulated healthy 
human PBMC. 
 
 
Methods 
 
Isolation of PBMC   
Peripheral venous blood was taken by 
venipuncture from 10 healthy donors after the 
approval of the Ethics Board of Medical Faculty, 
Trakia University. Each volunteer was informed and 
signed informed consent. The samples (10 ml) were 
collected in sterile tubes with EDTA. Peripheral blood 
mononuclear cells (PBMC) were harvested after 
density gradient centrifugation over Histopaque-1077.  
 
 
In vitro culturing 
PBMC (1 x 10
6
 cells/ml) cultures were 
prepared as described previously by Dobreva et al. 
[13]. They were stimulated with: 30 μg/ml C3 binding 
glycoprotein, (C3bgp) [14]; or 1 μg/ml 
Lipopolysaccharide (LPS) from Escherichia coli 
(Sigma-Aldrich-Merck, Darmstadt, Germany). PBMC 
cultures were incubated at 37
o
C for 6 and 24h. After 
incubation the separated supernatants were stored at 
-70
o
C. 
 
HDAC inhibition 
SAHA (Sigma-Aldrich-Merck, Darmstadt, 
Germany) (5 μM) was used for the inhibition of histone 
deacetylases. The inhibitor was added one h before 
stimulation.  
 
Cytokine evaluation 
Assessment of IL-18 and TNF-α was 
performed by ELISA, under to the manufacturer’s 
instructions. For the detection of TNF-α, R&D 
Systems Qantikine ELISA kit (Minneapolis, MN 
55413, USA) was used. IL-18 production was 
measured using commercially available kits 
purchased from MBL International Corporation 
(Woburn, MA 01801, USA). The colour reaction was 
measured as OD units and expressed in pg/ml. The 
sensitivity of the ELISA kits was 12 pg/ml for IL-18 
and 15 pg/ml for TNF-α. 
 
Statistical analysis 
The data was presented as means and 
standard error of the mean. Evaluation of the 
statistical differences between cultures was performed 
by Student’s t-test. Differences were significant when 
the P value was equal or less than 0.05. 
 
 
Results 
 
TNF-α production was suppressed by 
SAHA 
Results presented in Figure 1 demonstrated 
that C3bgp and LPS increased significantly TNF-α 
production at 6 and 24 h in comparison with 
nonstimulated controls (p < 0.05). The addition of 
SAHA to stimulated cultures leads to significantly 
decreased TNF-α production at 6 and in higher 
degree at 24 h. TNF-α quantity secreted by PBMC 
cultured with HDAC inhibitor was 4 to 6-fold less than 
in cultured PBMC without SAHA at six h and 5 to 8 
fold less at 24 h.  
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Figure 1: TNF-α production from stimulated with LPS and C3bgp PBMC after 
inhibition of HDAC by five μM SAHA at 6 and 24 h. P value between 
stimulated cultures without SAHA and stimulated cultures with SAHA is 
indicated on the figure 
 
SAHA did not modulate significantly IL-18 
production  
The addition of C3bgp and LPS leads to 
significantly more IL-18 production in comparison with 
nonstimulated cultures (p < 0.05). Moreover, we did 
not observe significant differences between 6 and 24 
h in the secretion of IL-18 from stimulated cultures. 
The inhibition of HDAC slightly decreased IL-18 
production. However, we did not detect significant 
differences between stimulated cultures treated with 
SAHA and cultures without SAHA as shown in Figure 
2. 
 
Figure 2: IL-18 production from stimulated with LPS and C3bgp PBMC after 
inhibition of HDAC by five μM SAHA at 6 and 24h 
 
 
 
Discussion 
 
IL-18 and TNF-α are proinflammatory 
cytokines, with a different effect on the acquired 
immunity and different production and regulatory 
mechanism as well. Whereas TNF-α gene expression 
and secretion is mediated through the TLR signalling 
pathway, IL-18 required proteolytic processing by 
Casp-1 in inflammasome before its secretion [11]. In 
the current study, we evaluated the effect of the 
histone deacetylases inhibitor SAHA on the gene 
expression and secretion of both cytokines, IL-18 and 
TNF-α, according to their contribution to the cancer 
development and anticancer immunity.  
TNF-α is a main proinflammatory cytokine 
identified for the first time because of its rapid cytolytic 
effect on some experimental cancers [15].  Recently, 
new studies showed that TNF-α has protumorigenic 
activity and is involved in all key points of 
tumorigenesis – tumour promotion, malignant 
transformation, tumour cell proliferation, angiogenesis 
and malignant cell spreading [9]. This investigation 
showed that the addition of the HDAC inhibitor SAHA 
downregulated the production of TNF-α released by 
the stimulated mononuclear cells. The same results 
were obtained from other authors [16]. Today is 
accepted that histone deacetylation is linked to the 
decreased gene transcription. Nevertheless, there 
was experimental evidence demonstrating that the 
treatment with HDI downregulated the expression of 
some proinflammatory cytokines by a mechanism 
which currently is being studied extensively. For 
example, Takada et al. demonstrated that HDI SAHA 
did not affect the binding of NF-kB transcription factor 
to the promotors of the target genes, but inhibited 
IkBα kinase activation, IkBα phosphorylation and 
translocation of p65 to the nucleus [17]. It is widely 
accepted that TNF-α production in response to LPS is 
mediated by TLR4 followed by the activation of NF-
kB. Our study demonstrated that SAHA 
downregulated TNF-α production after stimulation with 
LPS. Therefore, our results are in accordance with 
decisions of the other investigators [17][18] that the 
downregulating effect of SAHA on the 
proinflammatory cytokine production is mediated by 
the suppression of NF-kB transduction pathway. 
Previously we showed that C3bgp activated JNK and 
p38 intracellular transduction pathways [19]. 
Furthermore, our results showing that SAHA inhibited 
C3bgp-mediated TNF-α production are in 
concordance with the study of Ajizian et al., 
demonstrating that the suppression of p38 MAPK 
leads to downregulated TNF-α production [20] and 
with the study of Choo and coauthors, showing that 
SAHA affected p38 activation [21].    
Currently, it is widely accepted that IL-18 
drives the Th1 immune response, because induces 
IFN- secretion from T cells and natural killer cells 
[12]. There is evidence that treatment with IL-18 of 
experimental animals has significant antitumor action 
[11]. Moreover, in vivo IL-18 administration in 
experimental mice inoculated with tumour cell line 
stimulated IFN- production and IL-12 independent 
antitumor response [22]. Its elevated levels have been 
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observed in several types of cancers, especially in 
advanced cancers with metastasis [23][24][25]. Our 
study indicated that SAHA did not influence 
significantly IL-18 production from PBMC. There are 
few studies about SAHA and its effect on IL-18 
secretion. However, our results contradict the study of 
Choo et al., which demonstrated that SAHA inhibits 
the production of IL-18 in E11 and THP-1 cell lines in 
a dose-dependent manner [26]. One explanation for 
this discrepancy may be the different cell sources of 
IL-18. Our experiments were done with PBMC from 
healthy donors. In their study Choo et al., used E11 
cell line of human rheumatoid synovial cells, 
transformed with simian virus 40 large T antigen 
expression vector or a THP-1 monocytic cell line 
derived from a patient with acute myeloid leukaemia. 
Moreover, it is well known that the tumour cell lines 
had specific regulation of the gene expression in 
comparison with normal human cells [27]. 
Recently, it is widely accepted that chronic 
inflammation has a crucial role in the tumour-
promoting and survival, regardless of its origin. In this 
process, proinflammatory cytokines play a key role 
[28]. Many studies indicated that SAHA suppresses 
proinflammatory cytokines like IL-12, IFN-γ, TNF-α 
and IL-1β expression [13][16]. However, not always 
the inhibition of IL-12 and IFN-γ has positive effects, 
because of their immunoregulatory function as 
cytokines triggering cell-mediated anticancer 
immunity.  Our study has shown that treatment with 
SAHA leads to decreased TNF-α and unmodified IL-
18 production by PBMC-a surprising effect on the 
synthesis and secretion of both cytokines. 
Considering the protumorigenic activity of TNF-α, the 
downregulation of its production is a desirable effect 
of treatment with various histone deacetylase 
inhibitors including SAHA. However, IL-18 like IL-12 
has antitumorigenic activity because of its property to 
induce Th1 cell-mediated type of the immune 
response. Therefore, under immunosuppression 
triggered by SAHA, an unaffected IL-18 production 
may have a crucial role in the realization of antitumor 
immunity. Thus, this SAHA-specific modulation of the 
TNF-α and IL-18 production may provide a further 
clinical advantage for the treatment of various 
malignant conditions. 
In summary, our study showed that HDAC 
inhibitor SAHA downregulated TNF-α production and 
did not affect IL-18 secretion from activated PBMC.  
Therefore, we conclude that the production of TNF-α 
is mediated by HDAC class I and class II enzymes, 
but they are not involved in inflammasome-dependent 
regulation of biologically active IL-18 secretion. This 
different regulation of both cytokines by histone 
deacetylases and their inhibitors may be used in the 
development a new approach in the therapy of certain 
types of cancers.  
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